precision medicine for ophthalmology

Character is a precision medicine company that is unlocking the patterns of progressive polygenic diseases, with an initial focus on macular degeneration. Age-related macular degeneration (AMD) impacts one in eight people over the age of fifty and is a leading cause of blindness globally. Our mission is to use human genetics to understand what drives disease progression so we can discover and develop targeted therapies to more effectively treat patients - many of whom lack any treatment options today.

precision medicine for ophthalmology

Character is a precision medicine company that is unlocking the patterns of progressive polygenic diseases, with an initial focus on macular degeneration. Our mission is to use human genetics to understand what drives disease progression so we can discover and develop targeted therapies to more effectively treat patients - many of whom lack any treatment options today.

polygenic diseases
are not monolithic

In the past, many polygenic diseases have been treated as homogeneous with very little granularity.

we're unlocking the
patterns of ophthalmic diseases

The presentation and progression of polygenic diseases are as diverse as the patients they impact. That's why we are building world-class clinical genomic databases in AMD and primary open-angle glaucoma (POAG) to characterize the diversity of patient subtypes and discover the genetic drivers of disease progression.

polygenic diseases
are not monolithic

In the past, many polygenic diseases have been treated as homogenous with very little granularity.

we're unlocking
the patterns of ophthalmic diseases

The presentation and progression of polygenic diseases are as diverse as the patients they impact. That’s why we are building world-class clinical genomic databases in AMD and primary open-angle glaucoma (POAG)  to characterize the diversity of patient subtypes and discover the genetic drivers of disease progression.

addressing the nuances in
disease progression

Character is working to increase the probability of success for translating our discoveries into medicines by identifying the right drug targets for the right patients. Character partners with patients, providers, payers, and scientists on observational research studies that integrate genomics with longitudinal clinical data, imaging, and quantitative modeling of disease progression. This platform is the foundation for Character's drug discovery and development pipeline.

Integrated Patient Data
Drug target
selection
Medical records, ophthalmic imaging, and AI/ML powered quantification of disease progression phenotypes and clinical endpoints
Clinical endpoint prioritization
Identify endpoints that best track patient disease progression
In-house drug discovery and development
Learn more about our Pipeline of genetically-supported therapeutic programs
Patient stratification
Develop and evaluate multimodal patient biomarkers

the character precision medicine platform

Our patient network and integrated data platform power drug discovery and development by enabling prioritization of drug pathways and targets associated with disease progression, clinical trial optimization with patient stratification, and accelerated clinical trial execution.

Hover over left image for more.

Tap the image above for more.

Volumetric OCT: Dry age-related macular degeneration
Fundus autofluorescence: Dry age-related macular degeneration

let's solve polygenic diseases together

Provider Partnerships

By working with ophthalmologists and other treating physicians, we are determined to understand how diseases behave in real life and tackle the largest unmet needs.

Patient
Research

As a patient, you have an opportunity to contribute to research that could deliver better treatments for you and others like you in the future.

Industry Partnerships

As champions of human genetics-based drug discovery and development in ophthalmology, we are harnessing the power of integrated patient data, genomics and machine learning to develop transformative medicines.